[Anti thrombotic therapy after coronary thrombolysis].
Tani
Shigemasa
S
Department of Cardiology, Surugadai Nihon University Hospital.
Kanmatsuse
Katsuo
K
D000925:Anticoagulants / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage; D023903:Coronary Restenosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015425:Myocardial Reperfusion; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D015912:Thrombolytic Therapy; D013988:Ticlopidine / Q000008:administration & dosage; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D006493:Heparin; D010959:Tissue Plasminogen Activator; D013988:Ticlopidine; D001241:Aspirin